Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial계층적 복합 종점을 기반으로 한 연구의 설계 및 분석: DARE-19 시험의 통찰력Article Published on 2022-09-012022-09-11 Journal: Therapeutic innovation & regulatory science [Category] 임상, [키워드] accompanied Analysis analyzed cardiometabolic Cardiometabolic risk factors clinical endpoint Clinical endpoints Clinical outcome clinical outcomes clinically component components Composite composite endpoint COVID-19 COVID-19 pneumonia Dapagliflozin described detectable disease Effect Endpoint example flexible handling Hierarchical composite endpoints hospitalized patient hospitalized patients ICH include inhibitor insight Interpretation mechanism mechanism of action Missing data offered Pneumonia power primary endpoints randomized trial ranking Sample size SGLT2 inhibitors statistical suggested the primary endpoint therapeutic to define Treatment Trial Win odds. with COVID-19 [DOI] 10.1007/s43441-022-00420-1 PMC 바로가기 [Article Type] Article
Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, ChinaRandomized Controlled Trial Published on 2022-08-132022-10-05 Journal: Journal of Diabetes Research [Category] 임상, [키워드] adverse events blood glucose blood pressure center change China clinical Controlled coronavirus disease COVID-19 COVID-19 outbreak COVID-19 pandemic Dapagliflozin drug Effect Efficacy fasting blood Glucose group LDL-C Liraglutide Low-Density Lipoprotein cholesterol metabolic not significantly different obesity Occurrence overweight pandemic Patient randomised receive recruited Research Safety SBP significantly systolic Tianjin Type type 2 diabete [DOI] 10.1155/2022/4126995 PMC 바로가기 [Article Type] Randomized Controlled Trial
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 studyCOVID-19에 감염된 환자의 레닌-안지오텐신-알도스테론 시스템 관점에서 나트륨 포도당 공동 수송체 -2 억제제의 효과 평가: COVID-19 연구 환자의 호흡 부전에 대한 다파글리플로진의 결과 맥락화Review Published on 2022-03-012022-09-11 Journal: Molecular biology reports [Category] SARS, 신약개발, 임상, [키워드] ACE-2 aldosterone angiotensin antidiabetic Cardiorenal Disease carried cascade cell entry receptor Clinical findings Complication contribute Course COVID-19 COVID-19 pathology CVD Dapagliflozin DARE-19 demonstrated diabetes Diabetes Mellitus disease drug Effect Efficacy Evaluating exacerbate Glucose include infected with COVID-19 Infection inhibitor Numerous outcome Patient patients with COVID-19 Perspective RAAS reducing Renin Renin angiotensin aldosterone system Respiratory failure SARS-CoV2 severity SGLT-2. sodium statistical significance Treatment type 2 diabete Type 2 diabetes mellitus [DOI] 10.1007/s11033-022-07183-w PMC 바로가기 [Article Type] Review
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trialClinical Trial Published on 2021-09-012022-10-05 Journal: The lancet. Diabetes & endocrinology [Category] 임상, [키워드] 1:1 95% CI acute illness adverse event affecting assigned AstraZeneca atherosclerotic benefit cardiometabolic risk factor cardiovascular disease Chronic kidney disease clinical recovery clinical status COVID-19 Critically ill Dapagliflozin death dose double-blind dysregulated hazard ratio heart failure hospitalised hypertension inhibitor intention-to-treat kidney medication multiorgan failure occurred organ organ dysfunction outcome outcomes Patient patients treated patients with COVID-19 phase 3 trial Placebo placebo-controlled placebo-controlled trial Primary outcome Protective randomised Randomly Registered reported risk reduction Safety Serious Adverse Events statistically significant the placebo group Treatment type 2 diabetes were assessed were excluded with COVID-19 worsened [DOI] 10.1016/S2213-8587(21)00180-7 PMC 바로가기 [Article Type] Clinical Trial
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept다파글리플로진은 당뇨병이 있거나 없는 고위험 환자에서 COVID-19 진행을 약화시킬 수 있습니까? DARE-19 개념 뒤에Review Published on 2021-07-012022-09-11 Journal: Journal of cardiovascular pharmacology [Category] 임상, [키워드] clinical trial Comorbidity complications concept coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 progression Dapagliflozin diabete diabetes Effects epidemiological studies failure Glucose inhibitor respiratory Respiratory failure sodium [DOI] 10.1097/FJC.0000000000001011 PMC 바로가기 [Article Type] Review
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19Review Published on 2021-04-302023-06-15 Journal: Pulmonary pharmacology & therapeutics [Category] MERS, SARS, [키워드] Ambrisentan COVID-19 Dapagliflozin Endothelin antagonism Sodium glucose Co-Transporter-2 inhibition [DOI] 10.1016/j.pupt.2021.102035 PMC 바로가기 [Article Type] Review
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 studyCOVID-19로 인한 호흡 부전 환자의 주요 임상 사건 예방 및 회복에 대한 다파글리플로진의 효과: DARE-19 연구의 설계 및 근거Article Published on 2021-04-012022-09-11 Journal: Diabetes, obesity & metabolism [Category] SARS, 임상, [키워드] 1:1 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission Adult patients all-cause mortality atherosclerotic benefit cardiometabolic cardiometabolic risk factor cardiovascular cardiovascular disease caused Chronic kidney disease clinical recovery clinical status clinical trial composite endpoint coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 complications COVID-19-related complication COVID-19-related complications Critically ill Dapagliflozin diabetes double-blind Effect Efficacy Eligible patients Endpoint evaluate event Glucose heart failure Hierarchical high-risk patient High-risk patients Hospitalization hypothese IMPROVE incidence individuals with COVID-19 inhibitor International investigator-initiated kidney Kidney disease Kidney injury material morbidity and mortality multicentre multiorgan failure organ organ dysfunction Patient patient population patients hospitalized patients with COVID-19 phase III study Placebo placebo-controlled study Prevent Randomized Randomized controlled trial randomized trial reduce respiratory complication Respiratory complications Respiratory failure Safety safety profile SGLT2 inhibitor shown sodium Treatment type 2 diabete type 2 diabetes with COVID-19 worsened [DOI] 10.1111/dom.14296 PMC 바로가기 [Article Type] Article
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial코비드-19-실험 약물 및 기전(TACTIC-E)으로 입원한 ICu 전 환자에 대한 다중 암 치료 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-312022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] able to swallow adaptive Adaptive trial added Admission age Ambrisentan Analysis approved Arm ARMS balloon pump balloon pump) baseline benefit Biomarker blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not cardiac cardiovascular complications cells clearance clinical endpoint Clinical endpoints clinical picture clinically Combination comparator comparison Complete Composite Course COVID-19 COVID-19 infection creatinine creatinine clearance CRP Dapagliflozin Data analysis Day death defined demonstrated determine diabetes Diagnosis discretion disease dissemination drug drugs ECMO EDP1815 Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT Evidence evidence of exclusion criteria Experimental drugs failure feature fixed foundation Gault Gender group hypertension immunomodulation immunomodulatory incidence include Inclusion independent independent data monitoring committee Inotropes Intervention Invasive mechanical ventilation investigator Laboratory late stage male mechanism membrane neutrophil Neutrophils NHS number objective Occurrence on admission once daily Open-label open-label trial opinion option Organ failure organ support Other outcome Oxygenation pandemic Parallel Arm participant Patient patients with COVID-19 performed phase platform Platform trial positive positive COVID-19 predicted Primary outcome principal investigator progression protocol Radiographic radiological randomisation randomised Randomized controlled trial recruited reduce Registered related disease renal renal failure risk Sample size severity Standard of care status stratified Study protocol subject Support tablets the patient therapy Treatment treatment arm Trial Trial registration triggered Trust university website [DOI] 10.1186/s13063-020-04618-2 PMC 바로가기 [Article Type] Letter
Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19Review Published on 2020-06-282022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Admission advanced respiratory support approach approved Canagliflozin cardiovascular cardiovascular disease Chronic kidney disease clinical development clinical trial Clinical use Coronavirus disease 2019 COVID-19 COVID-19 patient Cytokine storm Dapagliflozin diabetes Diabetic effort Empagliflozin Factor faster Glucose include Inflammatory inhibitor kidney Ligand lung Mortality organ organ function organ support outcome pandemic potential benefit preclinical data PROTECT protection receiving renal replacing Repurposed drug Respiratory failure risk severe COVID-19 SGLT2 shown sodium Spread Support Therapies therapy thought thromboembolic complication Vaccine viral replication [DOI] 10.3390/jcm9072030 PMC 바로가기 [Article Type] Review